Drugs / Gadoquatrane
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | AMBELVIST | — | 2026-06-12 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05061979 | Oct 2021 → Mar 2022 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT06135181 | Aug 2020 → Feb 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT06125366 | Apr → Jun 2019 | — | Bayer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04307186 | Nov 2020 → Sep 2022 | central nervous system disorder | Bayer | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05915026 | Aug 2023 → Sep 2024 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT05915702 | Jul 2023 → May 2024 | central nervous system disorder | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT05915728 | Jul 2023 → May 2024 | nervous system disorder | Bayer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gadoquatrane | “The aim of this report was to characterize the key physicochemical, pharmacokinetic (PK), and magnetic resonance imaging (MRI) properties of gadoquatrane (BAY 1747846), a newly...” PMID 35703267 ↗ Jun 2022 |
| Known as | BAY1747846 | “Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg” NCT06135181 ↗6“Drug: Gadoquatrane (BAY1747846)” NCT05915026 ↗ “Gadoquatrane (BAY1747846)” NCT05915702 ↗ “Gadoquatrane (BAY1747846)” NCT05915728 ↗ “Gadoquatrane (BAY1747846)” NCT04307186 ↗ |
| Modality | Diagnostic / imaging agent | “Both BAY1747846 and gadobutrol are medicinal products known as gadolinium-based contrast agents (GBCA) which are used in MRI examinations to provide contrast enhancement and...” NCT04307186 ↗ |
| Route | Intravenous | “Solution for IV injection, single dose” NCT04307186 ↗ |